|
US6291425B1
(en)
*
|
1999-09-01 |
2001-09-18 |
Guilford Pharmaceuticals Inc. |
Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7928239B2
(en)
*
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
ATE538794T1
(de)
*
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
RU2319693C9
(ru)
|
1999-01-13 |
2008-08-20 |
Байер Копэрейшн |
Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
|
|
DK1690853T3
(da)
*
|
1999-01-13 |
2010-06-07 |
Bayer Healthcare Llc |
Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer
|
|
HU225780B1
(en)
*
|
1999-01-13 |
2007-08-28 |
Bayer Corp |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors and phareutical compositions containing them
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ES2228629T3
(es)
|
1999-11-22 |
2005-04-16 |
Smithkline Beecham Plc |
Derivados de imidazol y su uso como inhibidores de raf-quinasa.
|
|
GB0005357D0
(en)
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
|
AU2001235838A1
(en)
|
2000-03-06 |
2001-09-17 |
Smithkline Beecham Plc |
Imidazol derivatives as raf kinase inhibitors
|
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
|
EP1506962B1
(en)
|
2000-10-20 |
2008-07-02 |
Eisai R&D Management Co., Ltd. |
Nitrogen-containing aromatic heterocycles
|
|
JP2004517080A
(ja)
|
2000-11-29 |
2004-06-10 |
グラクソ グループ リミテッド |
Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
UA76977C2
(en)
|
2001-03-02 |
2006-10-16 |
Icos Corp |
Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
|
|
WO2002076930A2
(en)
*
|
2001-03-07 |
2002-10-03 |
Telik, Inc. |
Substituted diarylureas as stimulators for fas-mediated apoptosis
|
|
WO2002085857A2
(en)
*
|
2001-04-20 |
2002-10-31 |
Bayer Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
WO2003007955A2
(en)
*
|
2001-07-20 |
2003-01-30 |
Cancer Research Technology Limited |
Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
|
|
US20030216396A1
(en)
*
|
2002-02-11 |
2003-11-20 |
Bayer Corporation |
Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
SI1580188T1
(sl)
*
|
2002-02-11 |
2012-02-29 |
Bayer Healthcare Llc |
Aril sečnine kot kinazni inhibitorji
|
|
US10653684B2
(en)
|
2002-02-11 |
2020-05-19 |
Bayer Healthcare Llc |
Aryl ureas with angiogenisis inhibiting activity
|
|
AR037647A1
(es)
|
2002-05-29 |
2004-12-01 |
Novartis Ag |
Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
|
|
CN1671378A
(zh)
*
|
2002-08-01 |
2005-09-21 |
神经研究公司 |
用于治疗对抗血管生成疗法有应答的疾病的化合物
|
|
US7056925B2
(en)
|
2002-08-13 |
2006-06-06 |
Abbott Laboratories |
Urea kinase inhibitors
|
|
US20040034038A1
(en)
*
|
2002-08-13 |
2004-02-19 |
Goaquan Li |
Urea kinase inhibitors
|
|
WO2004064730A2
(en)
|
2003-01-14 |
2004-08-05 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
EP1603879A2
(en)
*
|
2003-02-28 |
2005-12-14 |
Bayer Pharmaceuticals Corporation |
Substituted pyridine derivatives useful in the treatment of cancer and other disorders
|
|
EP1608639A2
(en)
|
2003-02-28 |
2005-12-28 |
Bayer Pharmaceuticals Corporation |
Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
|
|
AU2004247626B8
(en)
|
2003-05-15 |
2011-05-19 |
Arqule, Inc. |
Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
|
|
EP1626714B1
(en)
|
2003-05-20 |
2007-07-04 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas for diseases mediated by pdgfr
|
|
BRPI0412263B1
(pt)
|
2003-07-22 |
2019-10-15 |
Arena Pharmaceuticals, Inc. |
Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
DE10334663A1
(de)
*
|
2003-07-30 |
2005-03-10 |
Merck Patent Gmbh |
Harnstoffderivate
|
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
|
BRPI0507198A
(pt)
*
|
2004-01-30 |
2007-06-26 |
Merck Patent Gmbh |
derivados de bisariluréia
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
US7812176B2
(en)
|
2004-03-23 |
2010-10-12 |
Arena Pharmaceuticals, Inc. |
Processes for preparing substituted N-aryl-N′-[3-(1H-pyrazol-5-YL) phenyl] ureas and intermediates thereof
|
|
WO2005110994A2
(en)
|
2004-04-30 |
2005-11-24 |
Bayer Pharmaceuticals Corporation |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
AU2005264988B2
(en)
|
2004-06-17 |
2011-09-22 |
Cytokinetics, Inc. |
Substituted urea derivatives for treating cardiac diseases
|
|
HUE032540T2
(en)
|
2004-06-24 |
2017-09-28 |
Vertex Pharma |
Modulators of ATP-binding cassette transporters
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
CN101010316A
(zh)
*
|
2004-07-02 |
2007-08-01 |
艾科斯有限公司 |
用于抑制chk1的化合物
|
|
WO2006010082A1
(en)
|
2004-07-08 |
2006-01-26 |
Arqule, Inc. |
1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
|
|
BRPI0514466A
(pt)
*
|
2004-08-19 |
2008-06-10 |
Icos Corp |
composto, composição, e, métodos de inibir a quinase 1 do ponto de controle em uma célula, de sensibilizar células, e de inibir a proliferação celular aberrante
|
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
|
AU2005293839B2
(en)
*
|
2004-10-13 |
2012-08-23 |
Merck Patent Gmbh |
Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
|
|
WO2006044869A1
(en)
|
2004-10-19 |
2006-04-27 |
Arqule, Inc. |
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
|
|
PE20061130A1
(es)
|
2004-11-19 |
2007-01-05 |
Arena Pharm Inc |
Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
|
|
PL1858877T3
(pl)
|
2005-01-14 |
2014-08-29 |
Gilead Connecticut Inc |
1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
|
|
JP2008526988A
(ja)
*
|
2005-01-14 |
2008-07-24 |
シージーアイ ファーマシューティカルズ，インコーポレーテッド |
キナーゼ活性モジュレーターとしての１，３−ジアリール置換尿素
|
|
CA2601955C
(en)
|
2005-03-07 |
2012-07-10 |
Bayer Healthcare Ag |
Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
|
|
US7777040B2
(en)
|
2005-05-03 |
2010-08-17 |
Cgi Pharmaceuticals, Inc. |
Certain substituted ureas, as modulators of kinase activity
|
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
WO2007018137A1
(ja)
|
2005-08-05 |
2007-02-15 |
Chugai Seiyaku Kabushiki Kaisha |
マルチキナーゼ阻害剤
|
|
US7825120B2
(en)
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
|
EP1959960B1
(en)
|
2005-12-15 |
2013-04-10 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
|
EP1959962A2
(en)
|
2005-12-16 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
US7989455B2
(en)
|
2005-12-19 |
2011-08-02 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
CA2635581C
(en)
|
2005-12-28 |
2017-02-28 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
USRE45337E1
(en)
|
2006-05-18 |
2015-01-13 |
Arena Pharmaceuticals, Inc. |
Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
|
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
|
EP2018371B1
(en)
|
2006-05-18 |
2015-03-04 |
Arena Pharmaceuticals, Inc. |
Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
EP2527329A1
(en)
|
2006-05-18 |
2012-11-28 |
Arena Pharmaceuticals, Inc. |
Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
|
|
WO2007139930A2
(en)
|
2006-05-26 |
2007-12-06 |
Bayer Healthcare Llc |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
|
EP2065372B1
(en)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
|
|
WO2008044688A1
(en)
*
|
2006-10-11 |
2008-04-17 |
Daiichi Sankyo Company, Limited |
Urea derivative
|
|
WO2008079972A2
(en)
|
2006-12-20 |
2008-07-03 |
Bayer Healthcare Llc |
4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
|
|
US8962655B2
(en)
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
|
US20080234332A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Xiong Cai |
Raf kinase inhibitors containing a zinc binding moiety
|
|
JP5393677B2
(ja)
|
2007-08-15 |
2014-01-22 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
|
|
WO2009035949A2
(en)
*
|
2007-09-13 |
2009-03-19 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors
|
|
CN101848895B
(zh)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
|
JP5511680B2
(ja)
*
|
2007-12-19 |
2014-06-04 |
キャンサー・リサーチ・テクノロジー・リミテッド |
ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用
|
|
JP2011513331A
(ja)
|
2008-02-29 |
2011-04-28 |
アレイ バイオファーマ、インコーポレイテッド |
ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
|
|
CA2716951A1
(en)
|
2008-02-29 |
2009-09-11 |
Array Biopharma Inc. |
Raf inhibitor compounds and methods of use thereof
|
|
CN101372475B
(zh)
*
|
2008-03-19 |
2012-01-04 |
南京工业大学 |
芳杂环取代的二苯脲类衍生物及其用途
|
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US9034911B2
(en)
|
2008-10-28 |
2015-05-19 |
Arena Pharmaceuticals, Inc. |
Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
EP2821400B1
(en)
|
2009-03-20 |
2017-09-27 |
Vertex Pharmaceuticals Incorporated |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2011025798A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Glaxosmithkline Llc |
Compounds and methods
|
|
US8980891B2
(en)
|
2009-12-18 |
2015-03-17 |
Arena Pharmaceuticals, Inc. |
Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
|
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
|
CA2805874A1
(en)
|
2010-07-19 |
2012-01-26 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
CN102134207B
(zh)
*
|
2011-01-14 |
2013-04-17 |
厦门大学 |
一种脲化合物及其制备方法和用途
|
|
MX2013009931A
(es)
|
2011-04-18 |
2013-10-01 |
Eisai R&D Man Co Ltd |
Agentes terapeuticos contra tumores.
|
|
EP2714937B1
(en)
|
2011-06-03 |
2018-11-14 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
EP2739139B1
(en)
*
|
2011-08-03 |
2019-09-25 |
National Taiwan University |
Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
|
|
RU2692779C2
(ru)
|
2012-02-27 |
2019-06-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтическая композиция и ее введения
|
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US9629851B2
(en)
|
2013-09-20 |
2017-04-25 |
Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis |
ROCK in combination with MAPK pathway
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
|
CN106573915B
(zh)
|
2014-08-01 |
2020-12-25 |
纽韦卢森公司 |
针对布罗莫结构域有活性的化合物
|
|
CN113683564A
(zh)
|
2014-08-28 |
2021-11-23 |
卫材R&D管理有限公司 |
高纯度喹啉衍生物及其生产方法
|
|
RU2749213C2
(ru)
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
|
US9638690B2
(en)
|
2014-11-07 |
2017-05-02 |
The University Of British Columbia |
Compounds and compositions for use as alkylating agent sensors and methods of use thereof
|
|
LT3263106T
(lt)
|
2015-02-25 |
2024-01-10 |
Eisai R&D Management Co., Ltd. |
Chinolino darinių kartumo sumažinimo būdas
|
|
CA2978226C
(en)
|
2015-03-04 |
2025-02-18 |
Eisai R&D Management Co., Ltd. |
COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
|
|
CN104744350A
(zh)
*
|
2015-03-11 |
2015-07-01 |
西安交通大学 |
一种吡啶取代的二芳基脲化合物及其制备方法和应用
|
|
CN104817493A
(zh)
*
|
2015-03-11 |
2015-08-05 |
西安交通大学 |
一种芳杂环酰胺取代的二芳基脲化合物及其制备方法和应用
|
|
WO2016201373A1
(en)
|
2015-06-12 |
2016-12-15 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
|
|
CN107801379B
(zh)
|
2015-06-16 |
2021-05-25 |
卫材R&D管理有限公司 |
抗癌剂
|
|
CA2992518A1
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
|
EP3330263B1
(en)
*
|
2015-07-30 |
2020-11-18 |
Chia Tai Tianqing Pharmaceutical Group Co.,Ltd |
Phenylurea derivatives as isocitrate dehydrogenase 2 inhibitors for treating cancer
|
|
RU2718048C2
(ru)
|
2015-08-20 |
2020-03-30 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
|
WO2018147275A1
(ja)
|
2017-02-08 |
2018-08-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
RU2019134940A
(ru)
|
2017-05-16 |
2021-06-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Лечение гепатоцеллюлярной карциномы
|
|
CN108997209B
(zh)
*
|
2018-06-11 |
2020-08-04 |
山东罗欣药业集团恒欣药业有限公司 |
一种瑞戈非尼的制备方法
|
|
MA52954A
(fr)
*
|
2018-06-21 |
2021-04-28 |
Cellestia Biotech Ag |
Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle
|
|
CN110128299B
(zh)
*
|
2019-05-13 |
2020-11-10 |
浙江大学 |
一种二苯基脲类抗肿瘤小分子抑制剂及其制备方法
|
|
CN113121484A
(zh)
|
2019-12-31 |
2021-07-16 |
复星弘创(苏州)医药科技有限公司 |
一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体
|
|
WO2022203395A1
(ko)
*
|
2021-03-23 |
2022-09-29 |
한국과학기술연구원 |
신규한 화합물 및 이를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
|